Dr Escudier explained that the biomarkers identify patients who will respond to this targeted agent — music to the manufacturers’ ears, I’m sure! It is interesting in the context of individualising therapy, and raises questions which are answered in part by other speakers we interviewed about tumour heterogeneity and the challenges of beating a multi-faceted and chameleon-like tumour.
Bernard Escudier MD, Institut Gustave Roussy, France
“Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy.”
Abstract No: 473
ASCO 2014 Genitourinary Cancers Symposium
